FARABURSEN INCREASES URINARY POLYCYSTIN 1 AND 2 AND REDUCES HEIGHT-ADJUSTED TOTAL KIDNEY VOLUME GROWTH IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/9dc96a67e06b23768003eaca2b1c2278.pdf
FARABURSEN INCREASES URINARY POLYCYSTIN 1 AND 2 AND REDUCES HEIGHT-ADJUSTED TOTAL KIDNEY VOLUME GROWTH IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Fouad T.
Chebib
Alan S. Yu ayu@kumc.edu The University of Kansas Medical Center, Kansas City, Kansas City, KS United States -
Rekha Garg rgarg@regulusrx.com Regulus Therapeutics, a Novartis Company, San Diego, San Diego, CA United States -
Keith A. Bellovich kbellov1@hfhs.org St. Clair Nephrology Research Detroit, Detroit, MI United States -
Arnold L. Silva asilva@boisekidney.com Boise Kidney and Hypertension Institute Boise Boise, ID United States -
Fouad T. Chebib chebib.fouad@mayo.edu Mayo Clinic in Florida Division of Nephrology and Hypertension Jacksonville, FL United States *
Claire Padgett cpadgett@regulusrx.com Regulus Therapeutics, a Novartis Company, San Diego San Diego, CA, United States -
Edmund C. Lee elee@regulusrx.com Regulus Therapeutics, a Novartis Company, San Diego San Diego, CA, United States -
Tania M. Valencia tvalencia@regulusrx.com Regulus Therapeutics, a Novartis Company, San Diego San Diego, CA, United States -
Timothy L. Kline kline.timothy@mayo.edu Mayo Clinic Minnesota Department of Radiology Rochester, MN United States -
Adriana Gregory gregory.adriana@mayo.edu Mayo Clinic Minnesota Radiology Rochester, MN United States -
Kevin Carroll kevin.carroll@kjcstatistics.co.uk KJC Statistics Limited Cheadle Cheadle United Kingdom -
Vishal Patel vishald.patel@utsouthwestern.edu The University of Texas Southwestern Medical Center Department of Internal Medicine, Division of Nephrology Dallas, Tx United States -
-
-
-